1. Scrip
  2. >>Focus On Asia

Kyorin Licenses Merck’s OAB Drug Vibegron For Japan

Kyorin Pharmaceuticals has entered into a licensing agreement with U.S.-based Merck & Co for the overactive bladder drug vibegron, hoping to expand its product lineup in the urology field.

Kyorin Pharmaceuticals has entered into a licensing agreement with U.S.-based Merck & Co for the overactive bladder drug vibegron, hoping to expand its product lineup in the urology field. The Japanese company will obtain exclusive development and sales rights for the drug in Japan, and will pay an undisclosed upfront lump sum plus milestone payments. Merck has already completed Phase II trials with the beta 3 adrenergic receptor agonist, and Kyorin plans to initiate domestic Phase III trials. Kyorin already sells Uritos (imidafenacin) for the condition in Japan, and with this deal hopes to further strengthen its position in the urology field. (Click Here For More – Japanese Language

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Japan

More from Focus On Asia

NIH Funding Cut Left Less Money On R&D Table, Tariffs Would Add To Woes: Aragen’s CEO

 
• By Vibha Ravi

Funding cuts at the National Institutes of Health, big pharma’s US onshoring moves, GCC partnerships and talks with the Indian government to solve intellectual property challenges are discussed in an interview with Aragen’s CEO, who is also keenly watching the Trump administration’s moves on pharma tariffs

Akeso Explains Ivonescimab Prelim OS Data After Investors’ Negative Reactions

 
• By Dexter Jie Yan

Akeso explains the circumstances behind the release of preliminary overall survival data from a head-to-head Phase III trial with ivonescimab in lung cancer, which some investors viewed as disappointing.

Novotech CEO On Flexible Trial Solutions Amid Tariff, Geopolitical Tensions

 
• By Anju Ghangurde

Novotech's CEO talks about rising interest for trials in regions with “regulatory agility” and “strategic insulation” from geopolitical complexity, especially among emerging and mid-sized biotech sponsors. Operational "reassessment” among some sponsors on exposure to China-based CROs/CRDMOs is another area he discussed.